Introducing the $100M SMART Antiviral Prize – Learn More!
VITAL is an accelerator hub in the U.S. Biomedical Advanced Research and Development Authority (BARDA) Accelerator Network (BAN). The BAN fosters growth of the global health security innovation ecosystem by supporting early-stage companies to overcome their business, marketing, and operational hurdles. VITAL supports development of innovative therapeutics solutions in alignment with BARDA’s mission to promote health security, and is managed by Start2 Group, with partners Advise Connect Inspire (ACI) and BioLabs.
VITAL supports health security innovators, startups, and portfolio companies by providing de-risking and accelerator services including entrepreneurship education and access to technical and business experts and resources.
VITAL provides non-dilutive funding to startups and academic innovators for the development, evaluation, and validation of innovative therapeutics solutions that align with BARDA’s strategic priorities.
Are you working on broad-spectrum small molecule antiviral therapies? VITAL seeks submissions for the SMART Antiviral Prize to fund breakthrough antiviral approaches with activity against members of the Togaviridae and Flaviviridae families – which include dengue, Zika, West Nile, and Chikungunya – that have the potential to advance into clinical trials and achieve U.S. regulatory approval.
Are you working on groundbreaking therapeutics solutions? The VITAL Hub seeks proposals for the development of innovative therapeutics solutions in alignment with BARDA’s mission to promote health security. Multi-use/platform technologies are preferred for this solicitation. VITAL invites startups and university-backed projects to apply for non-dilutive funding from $50K to $200K.
Are you working on protein-, including mAbs, and peptide-based therapeutic platforms? VITAL and BARDA are seeking proposals focused on preventing infections with influenza and other respiratory viruses. In particular, we are interested in transformative approaches that result in enhanced distribution of long-acting therapeutics to the upper and lower respiratory tracts.
VITAL and BARDA are seeking technologies and approaches that can predict and enable treatment benefit among patients for new or existing therapeutics that treat CBRN (chemical, biological, radiological or nuclear) threats, injuries, insults, infection or severe disease from other health security threats.
Are you a startup or university-based project pioneering the future of therapeutics? We’re looking for innovative solutions that align with BARDA’s mission to enhance pandemic preparedness and health security. Apply to the VITAL Accelerator Program and make a global impact!
Watch our info session to gain insights into the VITAL Biotech Accelerator Program and Funding opportunities.
Join us at the BARDA VITAL Hub Symposium in Berlin for cutting-edge insights on advancements in pandemic preparedness to combat infectious diseases and enhance global health security. Connect with global experts from the U.S., Canada, and EU to explore the latest discoveries and strategies in preventing and addressing global health crises.
